AndrewFrazierShorrMD
Pulmonology • Washington, DCCritical Care Medicine, Pleural Disease
Associate Professor, Medicine, Georgetown University School of Medicine
Dr. Shorr is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
110 Irving St NW
# 2A38
Washington, DC 20010Phone+1 202-877-2848Fax+1 202-877-6292
Education & Training
National Capital ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 1997 - 2000- National Capital ConsortiumResidency, Internal Medicine, 1994 - 1997
University of Virginia School of MedicineClass of 1995
Certifications & Licensure
DC State Medical License 2005 - 2027
MD State Medical License 2000 - 2025
PA State Medical License 1997 - 2000
VA State Medical License 1996 - 2000
American Board of Internal Medicine Critical Care Medicine- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Validating 4Ts for Heparin Induced Thrombocytopenia (HIT) Start of enrollment: 2009 Aug 01
- Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- Sustainable solutions to the continuous threat of antimicrobial resistance.Brad Spellberg, David N Gilbert, Michael Baym, Gonzalo Bearman, Tom Boyles
Health Affairs Scholar. 2025-02-01 - Comparative Outcomes of Meropenem-Vaborbactam vs. Ceftazidime-Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021.Marya D Zilberberg, Brian H Nathanson, Mark A Redell, Kate Sulham, Andrew F Shorr
Antibiotics. 2025-01-03 - Improving Outcomes in Nosocomial Pneumonia: Recent Evidence and More Challenges.Ihab H Masri, Bethany Busack, Andrew F Shorr
Pathogens. 2024-06-10
Press Mentions
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (Sulbactam for Injection; Durlobactam for Injection), Co-Packaged for Intravenous UseMay 23rd, 2023- FAQs: Improving Empiric Antibiotic Regimens for HABP/VABP in the ICUDecember 6th, 2022
- Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe PneumoniaAugust 25th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
